Cardiovascular pharmacology: An update

Anesthesiology Clinics

Volumn 28, Issue 4, 2010, Pages 723-738

  Liu, Henry ^a   Fox, Charles J ^a   Zhang, Shihai ^b   Kaye, Alan D ^c  

^a TULANE UNIVERSITY MEDICAL CENTER   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anesthesia; Cardiac myosin activators; Cardiovascular; CK 1827452; Clevedipine; Levosimendan; Nesiritide

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUCINDOLOL; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CK 1122534; CK 1213296; CK 1827452; CK 2017357; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; ENALAPRILAT; FUROSEMIDE; GLYCERYL TRINITRATE; HEPARIN; HYDRALAZINE; INOTROPIC AGENT; LEVOSIMENDAN; MILRINONE; NESIRITIDE; NITRIC ACID DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASODILATOR AGENT;

ABDOMINAL PAIN; ACTION POTENTIAL; ACUTE HEART FAILURE; BRADYCARDIA; BRONCHODILATATION; CAUSE OF DEATH; CHEST TIGHTNESS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DIASTOLE; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; DIASTOLIC HEART FAILURE; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAM; EXERCISE TOLERANCE; GLOMERULUS FILTRATION RATE; HEALTH CARE COST; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART OUTPUT; HEART PALPITATION; HEART RATE; HEART STROKE VOLUME; HEART VENTRICLE ARRHYTHMIA; HORMONAL REGULATION; HOSPITALIZATION; HOT FLUSH; HUMAN; HYPERTENSION; INSOMNIA; LOW DRUG DOSE; LUNG EDEMA; MORBIDITY; MORTALITY; NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PULMONARY ARTERY OCCLUSION PRESSURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SARCOMERE; SIDE EFFECT; SKELETAL MUSCLE; SMOOTH MUSCLE; SMOOTH MUSCLE RELAXATION; SYSTOLIC HEART FAILURE; TACHYCARDIA; UNITED STATES; VASODILATATION;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DIASTOLE; HEART FAILURE; HUMANS; HYDRAZONES; MUSCLE CONTRACTION; MYOFIBRILS; NATRIURETIC PEPTIDE, BRAIN; NICARDIPINE; PYRIDAZINES; PYRIDINES; SARCOMERES; UREA;

EID: 78149484990     PISSN: 19322275     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anclin.2010.09.001     Document Type: Review

References (17)

1. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2009, 119(3):480-486.
2. Baggish A.L., van Kimmenade R.R., Pinto Y., et al. New York Heart Association class versus amino-terminal pro-B type natriuretic peptide for acute heart failure prognosis. Biomarkers 2010, 15(4):307-314.
3. Kangawa K., Matsuo H. Purification and complete amino acid sequence of human atrial natriuretic polypeptide (alpha-hANP). Biochem Biophys Res Commun 1984, 118:131-139.
4. Bhardwaj A., Januzzi J.L. Natriuretic peptide-guided management of acutely destabilized heart failure: rationale and treatment algorithm. Crit Pathw Cardiol 2009, 8(4):146-150.
5. Reichert S., Ignaszewski A. Molecular and physiological effects of nesiritide. Can J Cardiol 2008, 24(Suppl B):15B-18B.
6. Elkayam U., Akhter M.W., Singh H., et al. Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure. Am J Cardiol 2004, 93(2):237-240.
7. Available at:, Accessed April 10, 2010. http://en.wikipedia.org/wiki/Cardiac_muscle.
8. Abraham W.T., Adams K.F., Fonarow G.C., et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005, 46:57-64.
9. Fellahi J.L., Parienti J.J., Hanouz J.L., et al. Perioperative use of dobutamine in cardiac surgery and adverse cardiac outcome: propensity-adjusted analyses. Anesthesiology 2008, 108(6):979-987.
10. Teerlink J.R. A novel approach to improve cardiac performance: cardiac myosin activators. Heart Fail Rev 2009, 14(4):289-298.
11. Teerlink J.R. Medscape Available at:, Accessed April 10, 2010. http://www.medscape.com/viewarticle/547591.
12. Available at:, Accessed April 10, 2010. http://en.wikipedia.org/wiki/Diastolic_dysfunction#Pathophysiology.
13. Zile M.R., Brutsaert D.L. Causal mechanisms and treatment new concepts in diastolic dysfunction and diastolic heart failure: part II. Circulation 2002, 105:1503-1508.
14. Kwak Y.L., Oh Y.J., Bang S.O., et al. Comparison of the effects of nicardipine and sodium nitroprusside for control of increased blood pressure after coronary artery bypass graft surgery. J Int Med Res 2004, 32:342-350.
15. Kenyon K.W. Clevidipine: an ultra short-acting calcium channel antagonist for acute hypertension. Ann Pharmacother 2009, 43(7):1258-1265.
16. Varon J, Peacock W, Garrison N, et al. Prolonged infusion of clevidipine results in safe and predictable blood pressure control in patients with acute severe hypertension. Paper presented at the Annual Meeting of the American College of Chest Physicians. Chicago, October 20-25, 2007.
17. Nguyen H.M., Ma K., Pham D.Q. Clevidipine for the treatment of severe hypertension in adults. Clin Ther 2010, 32:11-12.